Inhixa (Enoxaparin Sodium)

Enoxaparin sodium enhances the activity of antithrombin III, which selectively blocks factor Xa and, to a lesser extent, thrombin (factor IIa). This inhibition interferes with the coagulation cascade, decreasing thrombin generation and fibrin clot formation while preserving normal platelet function.

The dosage of Inhixa is individualized by the prescribing clinician based on the specific indication, patient weight, renal function, and clinical situation. Healthcare providers determine the appropriate amount and frequency according to established guidelines and patient needs.

Safety data for enoxaparin sodium in pregnancy and lactation are limited. It may be used when the potential benefit outweighs the risk, but the decision should be made by a qualified healthcare professional after careful assessment of maternal and fetal considerations.

To order Inhixa, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Compared with unfractionated heparin, enoxaparin sodium offers more predictable pharmacokinetics, a longer half‑life, and does not require routine laboratory monitoring. It provides a lower risk of heparin‑induced thrombocytopenia and can be administered subcutaneously, offering greater convenience than continuous intravenous infusion.

Inhixa should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and sterility.

Inhixa is supplied as a sterile solution for subcutaneous, intravenous, or haemodialysis administration. The route and technique are selected by the healthcare professional according to the indication, with subcutaneous injection being the most common method for prophylaxis and treatment of thromboembolic events.

The most serious risks include major bleeding (intracranial, gastrointestinal), heparin‑induced thrombocytopenia, and spinal or epidural hematoma, especially when combined with neuraxial procedures. Prompt recognition of these events and immediate medical attention are essential.

Inhixa is contraindicated in patients with active major bleeding, known hypersensitivity to enoxaparin or heparin products, and those with severe uncontrolled hypertension. Caution is also advised for individuals with a history of heparin‑induced thrombocytopenia or recent spinal/epidural anesthesia.